Discover how Mayo Clinic Digital Pathology, powered by NVIDIA and Aignostics, is leveraging AI and vast datasets to revolutionize diagnostics, accelerate medical breakthroughs, and improve patient outcomes worldwide.
Research finds patients with ASXL1 have distinctive epigentic changes that can activate harmful genes
The partnership will accelerate clinical validation and commercialization of certain NGS, mass spectrometry and immunology diagnostic tools
Research study intends to develop vocal biomarker for pulmonary hypertension
Dr. Megan Allyse from the Mayo Clinic Center for Individualized Medicine explains why gene editing is not yet suitable for medical practice
